関連レポート

抗HER2抗体の世界市場：2034年予測

出版元：Transparency Market Research  出版元について

発行年：2024年4月

定価：Single User License $5795 Multi User License $8795 Corporate User License $11795

ご請求は円換算（お見積り日TTSレート）となります。

ご予算に応じた各種ご提案も承ります。詳細はお問い合わせください。

納品形態：PDF by Email

当調査レポートは英文 237ページになります。

商品コード：TMR257

当レポートは発行年月に関わらず、受注の都度、最新情報にアップデートしてお届けいたします。ご希望情報の追加等もご相談可能です。

レポート紹介

エリスロポイエチン製剤の世界市場規模は2023年で94億ドル、2034年に143億ドル、市場の平均年成長率は3.8%増で推移するとみられます。

当レポートでは、エリスロポイエチン製剤の市場予測-2034年、各種セグメント別市場分析(薬剤クラス別、用途別、国地域別、等)、パイプライン分析、市場ダイナミクス、主要企業プロフィールなどの情報を盛り込み、概略以下の構成でお届けいたします。

【レポート構成概要】
■エリスロポイエチン製剤の世界市場予測2020-2034年
・市場規模(US$)

■薬剤クラス別、市場-2034年
エポエチンアルファ
エポエチン ベータ
ダルベポエチンアルファ
その他
※(市場規模US$)

■薬剤タイプ別、市場-2034年
生物製剤
バイオシミラー
※(市場規模US$)

■用途別、市場-2034年
癌
腎疾患
血液学
神経
その他
※(市場規模US$)


■販売チャネル別、市場-2034年
病院薬局
小売薬局
オンライン薬局
※(市場規模US$)

■主要国地域別市場-2034年
北米
・米国、カナダ
欧州
・英国、ドイツ、フランス、スペイン、イタリア
・その他欧州
アジア太平洋
・日本、中国、インド
・オーストラリア/ニュージーランド
・その他アジア太平洋
中東アフリカ
・GCC諸国、南アフリカ
・その他中東アフリカ
中南米
・ブラジル、メキシコ
・その他中南米
※地域別に各種セグメント別の細分化データ掲載、詳細は目次参照


■市場分析
市場ダイナミクス（ドライバー、阻害要因、機会）
パイプライン分析
主な合併買収
競合状況

■エリスロポイエチン製剤の主要企業プロフィール動向
Amgen Inc.
Novartis AG
F. Hoffmann-La Roche Ltd.
GSK
Merck & Co., Inc.
Johnson & Johnson
Wockhardt Ltd.
Pfizer, Inc.
Biocon Ltd.
Teva Pharmaceutical Industries Ltd.

（全237頁）

Table of Contents (英文詳細目次）

1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Erythropoietin Drugs Market

4. Market Overview
4.1. Introduction
4.1.1. Product Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Erythropoietin Drugs Market Analysis and Forecast, 2020-2034

5. Key Insights
5.1. Pipeline Analysis
5.2. Key Product/Brand Analysis
5.3. Key Mergers & Acquisitions
5.4. COVID-19 Pandemic Impact on Industry

6. Global Erythropoietin Drugs Market Analysis and Forecast, by Drug Class
6.1. Introduction and Definitions
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Drug Class, 2020-2034
6.3.1. Epoetin Alfa
6.3.2. Epoetin Beta
6.3.3. Darbepoetin Alfa
6.3.4. Others
6.4. Market Attractiveness, by Drug Class

7. Global Erythropoietin Drugs Market Analysis and Forecast, by Drug Type
7.1. Introduction and Definitions
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Drug Type, 2020-2034
7.3.1. Biologics
7.3.2. Biosimilar
7.4. Market Attractiveness, by Drug Type

8. Global Erythropoietin Drugs Market Analysis and Forecast, by Drug Application
8.1. Introduction and Definitions
8.2. Key Findings/Developments
8.3. Market Value Forecast, by Drug Application, 2020-2034
8.3.1. Cancer
8.3.2. Renal Disease
8.3.3. Hematology
8.3.4. Neurology
8.3.5. Others
8.4. Market Attractiveness, by Drug Application

9. Global Erythropoietin Drugs Market Analysis and Forecast, by Distribution Channel
9.1. Introduction and Definitions
9.2. Key Findings/Developments
9.3. Market Value Forecast, by Distribution Channel, 2020-2034
9.3.1. Hospital Pharmacy
9.3.2. Retail Pharmacy
9.3.3. Online Pharmacy
9.4. Market Attractiveness, by Distribution Channel

10. Global Erythropoietin Drugs Market Analysis and Forecast, by Region
10.1. Key Findings
10.2. Market Value Forecast, by Region, 2020-2034
10.2.1. North America
10.2.2. Europe
10.2.3. Asia Pacific
10.2.4. Latin America
10.2.5. Middle East & Africa
10.3. Market Attractiveness, by Region

11. North America Erythropoietin Drugs Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Drug Class, 2020-2034
11.2.1. Epoetin Alfa
11.2.2. Epoetin Beta
11.2.3. Darbepoetin Alfa
11.2.4. Others
11.3. Market Attractiveness, by Drug Class
11.4. Market Value Forecast, by Drug Type, 2020-2034
11.4.1. Biologics
11.4.2. Biosimilar
11.5. Market Attractiveness, by Drug Type
11.6. Market Value Forecast, by Drug Application, 2020-2034
11.6.1. Cancer
11.6.2. Renal Disease
11.6.3. Hematology
11.6.4. Neurology
11.6.5. Others
11.7. Market Attractiveness, by Drug Application
11.8. Market Value Forecast, by Distribution Channel, 2020-2034
11.8.1. Hospital Pharmacy
11.8.2. Retail Pharmacy
11.8.3. Online Pharmacy
11.9. Market Attractiveness, by Distribution Channel
11.10. Market Value Forecast, by Country/Sub-region, 2020-2034
11.10.1. U.S.
11.10.2. Canada
11.11. Market Attractiveness Analysis
11.11.1. By Drug Class
11.11.2. By Drug Type
11.11.3. By Drug Application
11.11.4. By Distribution Channel
11.11.5. By Country

12. Europe Erythropoietin Drugs Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Drug Class, 2020-2034
12.2.1. Epoetin Alfa
12.2.2. Epoetin Beta
12.2.3. Darbepoetin Alfa
12.2.4. Others
12.3. Market Attractiveness, by Drug Class
12.4. Market Value Forecast, by Drug Type, 2020-2034
12.4.1. Biologics
12.4.2. Biosimilar
12.5. Market Attractiveness, by Drug Type
12.6. Market Value Forecast, by Drug Application, 2020-2034
12.6.1. Cancer
12.6.2. Renal Disease
12.6.3. Hematology
12.6.4. Neurology
12.6.5. Others
12.7. Market Attractiveness, by Drug Application
12.8. Market Value Forecast, by Distribution Channel, 2020-2034
12.8.1. Hospital Pharmacy
12.8.2. Retail Pharmacy
12.8.3. Online Pharmacy
12.9. Market Attractiveness, by Distribution Channel
12.10. Market Value Forecast, by Country/Sub-region, 2020-2034
12.10.1. Germany
12.10.2. U.K.
12.10.3. France
12.10.4. Italy
12.10.5. Spain
12.10.6. Rest of Europe
12.11. Market Attractiveness Analysis
12.11.1. By Drug Class
12.11.2. By Drug Type
12.11.3. By Drug Application
12.11.4. By Distribution Channel
12.11.5. By Country/Sub-region

13. Asia Pacific Erythropoietin Drugs Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Drug Class, 2020-2034
13.2.1. Epoetin Alfa
13.2.2. Epoetin Beta
13.2.3. Darbepoetin Alfa
13.2.4. Others
13.3. Market Attractiveness, by Drug Class
13.4. Market Value Forecast, by Drug Type, 2020-2034
13.4.1. Biologics
13.4.2. Biosimilar
13.5. Market Attractiveness, by Drug Type
13.6. Market Value Forecast, by Drug Application, 2020-2034
13.6.1. Cancer
13.6.2. Renal Disease
13.6.3. Hematology
13.6.4. Neurology
13.6.5. Others
13.7. Market Attractiveness, by Drug Application
13.8. Market Value Forecast, by Distribution Channel, 2020-2034
13.8.1. Hospital Pharmacy
13.8.2. Retail Pharmacy
13.8.3. Online Pharmacy
13.9. Market Attractiveness, by Distribution Channel
13.10. Market Value Forecast, by Country/Sub-region, 2020-2034
13.10.1. China
13.10.2. Japan
13.10.3. India
13.10.4. Australia & New Zealand
13.10.5. Rest of Asia Pacific
13.11. Market Attractiveness Analysis
13.11.1. By Drug Class
13.11.2. By Drug Type
13.11.3. By Drug Application
13.11.4. By Distribution Channel
13.11.5. By Country/Sub-region

14. Latin America Erythropoietin Drugs Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Drug Class, 2020-2034
14.2.1. Epoetin Alfa
14.2.2. Epoetin Beta
14.2.3. Darbepoetin Alfa
14.2.4. Others
14.3. Market Attractiveness, by Drug Class
14.4. Market Value Forecast, by Drug Type, 2020-2034
14.4.1. Biologics
14.4.2. Biosimilar
14.5. Market Attractiveness, by Drug Type
14.6. Market Value Forecast, by Drug Application, 2020-2034
14.6.1. Cancer
14.6.2. Renal Disease
14.6.3. Hematology
14.6.4. Neurology
14.6.5. Others
14.7. Market Attractiveness, by Drug Application
14.8. Market Value Forecast, by Distribution Channel, 2020-2034
14.8.1. Hospital Pharmacy
14.8.2. Retail Pharmacy
14.8.3. Online Pharmacy
14.9. Market Attractiveness, by Distribution Channel
14.10. Market Value Forecast, by Country/Sub-region, 2020-2034
14.10.1. Brazil
14.10.2. Mexico
14.10.3. Rest of Latin America
14.11. Market Attractiveness Analysis
14.11.1. By Drug Class
14.11.2. By Drug Type
14.11.3. By Drug Application
14.11.4. By Distribution Channel
14.11.5. By Country/Sub-region

15. Middle East & Africa Erythropoietin Drugs Market Analysis and Forecast
15.1. Introduction
15.1.1. Key Findings
15.2. Market Value Forecast, by Drug Class, 2020-2034
15.2.1. Epoetin Alfa
15.2.2. Epoetin Beta
15.2.3. Darbepoetin Alfa
15.2.4. Others
15.3. Market Attractiveness, by Drug Class
15.4. Market Value Forecast, by Drug Type, 2020-2034
15.4.1. Biologics
15.4.2. Biosimilar
15.5. Market Attractiveness, by Drug Type
15.6. Market Value Forecast, by Drug Application, 2020-2034
15.6.1. Cancer
15.6.2. Renal Disease
15.6.3. Hematology
15.6.4. Neurology
15.6.5. Others
15.7. Market Attractiveness, by Drug Application
15.8. Market Value Forecast, by Distribution Channel, 2020-2034
15.8.1. Hospital Pharmacy
15.8.2. Retail Pharmacy
15.8.3. Online Pharmacy
15.9. Market Attractiveness, by Distribution Channel
15.10. Market Value Forecast, by Country/Sub-region, 2020-2034
15.10.1. GCC Countries
15.10.2. South Africa
15.10.3. Rest of Middle East & Africa
15.11. Market Attractiveness Analysis
15.11.1. By Drug Class
15.11.2. By Drug Type
15.11.3. By Drug Application
15.11.4. By Distribution Channel
15.11.5. By Country/Sub-region

16. Competition Landscape
16.1. Market Player - Competition Matrix (By Tier and Size of Companies)
16.2. Market Share Analysis, by Company (2023)
16.3. Company Profiles
16.3.1. Amgen, Inc.
16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.1.2. Product Portfolio
16.3.1.3. Financial Overview
16.3.1.4. SWOT Analysis
16.3.1.5. Strategic Overview
16.3.2. Novartis AG
16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.2.2. Product Portfolio
16.3.2.3. Financial Overview
16.3.2.4. SWOT Analysis
16.3.2.5. Strategic Overview
16.3.3. F. Hoffmann-La Roche Ltd.
16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.3.2. Product Portfolio
16.3.3.3. Financial Overview
16.3.3.4. SWOT Analysis
16.3.3.5. Strategic Overview
16.3.4. GCK
16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.4.2. Product Portfolio
16.3.4.3. Financial Overview
16.3.4.4. SWOT Analysis
16.3.4.5. Strategic Overview
16.3.5. Merck & Co., Inc.
16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.5.2. Product Portfolio
16.3.5.3. Financial Overview
16.3.5.4. SWOT Analysis
16.3.5.5. Strategic Overview
16.3.6. Johnson & Johnson
16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.6.2. Product Portfolio
16.3.6.3. Financial Overview
16.3.6.4. SWOT Analysis
16.3.6.5. Strategic Overview
16.3.7. Wockhardt Ltd.
16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.7.2. Product Portfolio
16.3.7.3. Financial Overview
16.3.7.4. SWOT Analysis
16.3.7.5. Strategic Overview
16.3.8. Pfizer, Inc.
16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.8.2. Product Portfolio
16.3.8.3. Financial Overview
16.3.8.4. SWOT Analysis
16.3.8.5. Strategic Overview
16.3.9. Biocon Ltd.
16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.9.2. Product Portfolio
16.3.9.3. Financial Overview
16.3.9.4. SWOT Analysis
16.3.9.5. Strategic Overview
16.3.10. Teva Pharmaceutical Industries Ltd.
16.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.10.2. Product Portfolio
16.3.10.3. Financial Overview
16.3.10.4. SWOT Analysis
16.3.10.5. Strategic Overview

List of Tables

Table 01: Global Erythropoietin Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2020-2034

Table 02: Global Erythropoietin Drugs Market Size (US$ Mn) Forecast, by Drug Type, 2020-2034

Table 03: Global Erythropoietin Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2020-2034

Table 04: Global Erythropoietin Drugs Market Size (US$ Mn) Forecast, by Drug Application, 2020-2034

Table 05: Global Erythropoietin Drugs Market Size (US$ Mn) Forecast, by Region, 2020-2034

Table 06: North America Erythropoietin Drugs Market Size (US$ Mn) Forecast, by Country, 2020-2034

Table 07: North America Erythropoietin Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2020-2034

Table 08: North America Erythropoietin Drugs Market Size (US$ Mn) Forecast, by Drug Type, 2020-2034

Table 09: North America Erythropoietin Drugs Market Size (US$ Mn) Forecast, by Drug Application, 2020-2034

Table 10: North America Erythropoietin Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2020-2034

Table 11: Europe Erythropoietin Drugs Market Size (US$ Mn) Forecast, by Country/Sub-region, 2020-2034

Table 12: Europe Erythropoietin Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2020-2034

Table 13: Europe Erythropoietin Drugs Market Size (US$ Mn) Forecast, by Drug Type, 2020-2034

Table 14: Europe Erythropoietin Drugs Market Size (US$ Mn) Forecast, by Drug Application, 2020-2034

Table 15: Europe Erythropoietin Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2020-2034

Table 16: Asia Pacific Erythropoietin Drugs Market Size (US$ Mn) Forecast, by Country/Sub-region, 2020-2034

Table 17: Asia Pacific Erythropoietin Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2020-2034

Table 18: Asia Pacific Erythropoietin Drugs Market Size (US$ Mn) Forecast, by Drug Type, 2020-2034

Table 19: Asia Pacific Erythropoietin Drugs Market Size (US$ Mn) Forecast, by Drug Application, 2020-2034

Table 20: Asia Pacific Erythropoietin Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2020-2034

Table 21: Latin America Erythropoietin Drugs Market Size (US$ Mn) Forecast, by Country/Sub-region, 2020-2034

Table 22: Latin America Erythropoietin Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2020-2034

Table 23: Latin America Erythropoietin Drugs Market Size (US$ Mn) Forecast, by Drug Type, 2020-2034

Table 24: Latin America Erythropoietin Drugs Market Size (US$ Mn) Forecast, by Drug Application, 2020-2034

Table 25: Latin America Erythropoietin Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2020-2034

Table 26: Middle East & Africa Erythropoietin Drugs Market Size (US$ Mn) Forecast, by Country/Sub-region, 2020-2034

Table 27: Middle East & Africa Erythropoietin Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2020-2034

Table 28: Middle East & Africa Erythropoietin Drugs Market Size (US$ Mn) Forecast, by Drug Type, 2020-2034

Table 29: Middle East & Africa Erythropoietin Drugs Market Size (US$ Mn) Forecast, by Drug Application, 2020-2034

Table 30: Middle East & Africa Erythropoietin Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2020-2034

List of Figures

Figure 01: Global Erythropoietin Drugs Market Size (US$ Mn), by Region, 2023 and 2034

Figure 02: Global Erythropoietin Drugs Market Revenue (US$ Mn), by Drug Class, 2023

Figure 03: Global Erythropoietin Drugs Market Value Share, by Drug Class, 2023

Figure 04: Global Erythropoietin Drugs Market Revenue (US$ Mn), by Drug Type, 2023

Figure 05: Global Erythropoietin Drugs Market Value Share, by Drug Type, 2023

Figure 06: Global Erythropoietin Drugs Market Revenue (US$ Mn), by Drug Application, 2023

Figure 07: Global Erythropoietin Drugs Market Value Share, by Drug Application, 2023

Figure 08: Global Erythropoietin Drugs Market Revenue (US$ Mn), by Distribution Channel, 2023

Figure 09: Global Erythropoietin Drugs Market Value Share, by Distribution Channel, 2023

Figure 10: Global Erythropoietin Drugs Market Value Share, by Region, 2023

Figure 11: Global Erythropoietin Drugs Market Value (US$ Mn) Forecast, 2020-2034

Figure 12: Global Erythropoietin Drugs Market Value Share Analysis, by Drug Class, 2023 and 2034

Figure 13: Global Erythropoietin Drugs Market Attractiveness Analysis, by Drug Class, 2024-2034

Figure 14: Global Erythropoietin Drugs Market Value Share Analysis, by Drug Type, 2023 and 2034

Figure 15: Global Erythropoietin Drugs Market Attractiveness Analysis, by Drug Type, 2024-2034

Figure 16: Global Erythropoietin Drugs Market Value Share Analysis, by Drug Application, 2023 and 2034

Figure 17: Global Erythropoietin Drugs Market Attractiveness Analysis, by Drug Application, 2024-2034

Figure 18: Global Erythropoietin Drugs Market Revenue (US$ Mn), by Distribution Channel, 2023

Figure 19: Global Erythropoietin Drugs Market Value Share, by Distribution Channel, 2023

Figure 20: Global Erythropoietin Drugs Market Value Share Analysis, by Region, 2023 and 2034

Figure 21: Global Erythropoietin Drugs Market Attractiveness Analysis, by Region, 2024-2034

Figure 22: North America Erythropoietin Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2020-2034

Figure 23: North America Erythropoietin Drugs Market Attractiveness Analysis, by Country, 2024-2034

Figure 24: North America Erythropoietin Drugs Market Value Share Analysis, by Country, 2023 and 2034

Figure 25: North America Erythropoietin Drugs Market Value Share Analysis, by Drug Class, 2023 and 2034

Figure 26: North America Erythropoietin Drugs Market Value Share Analysis, by Drug Type, 2023 and 2034

Figure 27: North America Erythropoietin Drugs Market Value Share Analysis, by Drug Application, 2023 and 2034

Figure 28: North America Erythropoietin Drugs Market Value Share Analysis, by Distribution Channel, 2023 and 2034

Figure 29: North America Erythropoietin Drugs Market Attractiveness Analysis, by Drug Class, 2024-2034

Figure 30: North America Erythropoietin Drugs Market Attractiveness Analysis, by Drug Type, 2024-2034

Figure 31: North America Erythropoietin Drugs Market Attractiveness Analysis, by Drug Application, 2024-2034

Figure 32: North America Erythropoietin Drugs Market Attractiveness Analysis, by Distribution Channel, 2024-2034

Figure 33: Europe Erythropoietin Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2020-2034

Figure 34: Europe Erythropoietin Drugs Market Attractiveness Analysis, by Country/Sub-region, 2024-2034

Figure 35: Europe Erythropoietin Drugs Market Value Share Analysis, by Country/Sub-region, 2023 and 2034

Figure 36: Europe Erythropoietin Drugs Market Value Share Analysis, by Drug Class, 2023 and 2034

Figure 37: Europe Erythropoietin Drugs Market Value Share Analysis, by Drug Type, 2023 and 2034

Figure 38: Europe Erythropoietin Drugs Market Value Share Analysis, by Drug Application, 2023 and 2034

Figure 39: Europe Erythropoietin Drugs Market Value Share Analysis, by Distribution Channel, 2023 and 2034

Figure 40: Europe Erythropoietin Drugs Market Attractiveness Analysis, by Drug Class, 2024-2034

Figure 41: Europe Erythropoietin Drugs Market Attractiveness Analysis, by Drug Type, 2024-2034

Figure 42: Europe Erythropoietin Drugs Market Attractiveness Analysis, by Drug Application, 2024-2034

Figure 43: Europe Erythropoietin Drugs Market Attractiveness Analysis, by Distribution Channel, 2024-2034

Figure 44: Asia Pacific Erythropoietin Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2020-2034

Figure 45: Asia Pacific Erythropoietin Drugs Market Attractiveness Analysis, by Country/Sub-region, 2024-2034

Figure 46: Asia Pacific Erythropoietin Drugs Market Value Share Analysis, by Country/Sub-region, 2023 and 2034

Figure 47: Asia Pacific Erythropoietin Drugs Market Value Share Analysis, by Drug Class, 2023 and 2034

Figure 48: Asia Pacific Erythropoietin Drugs Market Value Share Analysis, by Drug Type, 2023 and 2034

Figure 49: Asia Pacific Erythropoietin Drugs Market Value Share Analysis, by Drug Application, 2023 and 2034

Figure 50: Asia Pacific Erythropoietin Drugs Market Value Share Analysis, by Distribution Channel, 2023 and 2034

Figure 51: Asia Pacific Erythropoietin Drugs Market Attractiveness Analysis, by Drug Class, 2024-2034

Figure 52: Asia Pacific Erythropoietin Drugs Market Attractiveness Analysis, by Drug Type, 2024-2034

Figure 53: Asia Pacific Erythropoietin Drugs Market Attractiveness Analysis, by Drug Application, 2024-2034

Figure 54: Asia Pacific Erythropoietin Drugs Market Attractiveness Analysis, by Distribution Channel, 2023-2034

Figure 55: Latin America Erythropoietin Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2020-2034

Figure 56: Latin America Erythropoietin Drugs Market Attractiveness Analysis, by Country/Sub-region, 2024-2034

Figure 57: Latin America Erythropoietin Drugs Market Value Share Analysis, by Country/Sub-region, 2023 and 2034

Figure 58: Latin America Erythropoietin Drugs Market Value Share Analysis, by Drug Class, 2023 and 2034

Figure 59: Latin America Erythropoietin Drugs Market Value Share Analysis, by Drug Type, 2023 and 2034

Figure 60: Latin America Erythropoietin Drugs Market Value Share Analysis, by Drug Application, 2023 and 2034

Figure 61: Latin America Erythropoietin Drugs Market Value Share Analysis, by Distribution Channel, 2023 and 2034

Figure 62: Latin America Erythropoietin Drugs Market Attractiveness Analysis, by Drug Class, 2024-2034

Figure 63: Latin America Erythropoietin Drugs Market Attractiveness Analysis, by Drug Type, 2024-2034

Figure 64: Latin America Erythropoietin Drugs Market Attractiveness Analysis, by Drug Application, 2024-2034

Figure 65: Latin America Erythropoietin Drugs Market Attractiveness Analysis, by Distribution Channel, 2024-2034

Figure 66: Middle East & Africa Erythropoietin Drugs Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2020-2034

Figure 67: Middle East & Africa Erythropoietin Drugs Market Attractiveness Analysis, by Country/Sub-region, 2024-2034

Figure 68: Middle East & Africa Erythropoietin Drugs Market Value Share Analysis, by Country/Sub-region, 2023 and 2034

Figure 69: Middle East & Africa Erythropoietin Drugs Market Value Share Analysis, by Drug Class, 2023 and 2034

Figure 70: Middle East & Africa Erythropoietin Drugs Market Value Share Analysis, by Drug Type, 2023 and 2034

Figure 71: Middle East & Africa Erythropoietin Drugs Market Value Share Analysis, by Drug Application, 2023 and 2034

Figure 72: Middle East & Africa Erythropoietin Drugs Market Value Share Analysis, by Distribution Channel, 2023 and 2034

Figure 73: Middle East & Africa Erythropoietin Drugs Market Attractiveness Analysis, by Drug Class, 2024-2034

Figure 74: Middle East & Africa Erythropoietin Drugs Market Attractiveness Analysis, by Drug Type, 2024-2034

Figure 75: Middle East & Africa Erythropoietin Drugs Market Attractiveness Analysis, by Drug Application, 2024-2034

Figure 76: Middle East & Africa Erythropoietin Drugs Market Attractiveness Analysis, by Distribution Channel, 2024-2034

△ 一番上に戻る